Skip to main content
Top
Published in: Hepatology International 1/2022

01-02-2022 | Cholangiocarcinoma | Original Article

Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer

Authors: Tuo Deng, Jialiang Li, Bangjie He, Bo Chen, Fangting Liu, Ziyan Chen, Jiuyi Zheng, Zhehao Shi, Tan Zhang, Liming Deng, Haitao Yu, Jinhuan Yang, Lijun Wu, Yunfeng Shan, Zhengping Yu, Xiaolei Chen, Yi Wang, Gang Chen

Published in: Hepatology International | Issue 1/2022

Login to get access

Abstract

Background

Primary liver cancer has high mortality and morbidity worldwide. However, the characteristic of gut microbiota profile and its correlation with inflammation status in liver cancer patients remains largely unknown, and a gut microbiome-based diagnostic model for liver cancer is still absent.

Methods

Here, we provided a comprehensive analysis based on fecal 16S rRNA sequencing and clinical data in a cohort consisting of 40 healthy volunteers, 143 hepatocellular carcinoma (HCC) patients, and 46 cholangiocarcinoma (CCA) patients.

Results

Our results indicated a distinct shift of gut microbiota composition between two primary liver cancer types and compared with healthy volunteers. Based on the diversity constitute of gut microbiome taxonomy and random forest algorithm, eight genera with mean abundance above 0.1% were selected to construct the classification model with half of the randomly selected cohort. Based on this signature, high diagnostic accuracy in the validation cohort to classify liver cancer types (AUC = 0.989, 0.967, 0.920 for Control, HCC, CCA separately) was achieved. Further analysis showed increased Gram-negative bacteria and elevated inflammatory response markers in CCA group versus HCC group. The correlation analysis between inflammatory response markers and composition of gut microbiome revealed decreased potentially beneficial genus and increased opportunistic pathogens positively correlated with adverse prognostic inflammatory response markers.

Conclusion

Generally, our study established the gut microbiome-based signature for liver cancer prediction and screening and revealed that gut microbiome characteristic in primary liver cancer was correlated with adverse inflammatory response markers in liver cancer.
Appendix
Available only for authorised users
Literature
37.
go back to reference Shacter, E. & Weitzman, S. A. Chronic inflammation and cancer. Oncology (Williston Park, N.Y.) 16, 217–226, 229; discussion 230–212 (2002). Shacter, E. & Weitzman, S. A. Chronic inflammation and cancer. Oncology (Williston Park, N.Y.) 16, 217–226, 229; discussion 230–212 (2002).
Metadata
Title
Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer
Authors
Tuo Deng
Jialiang Li
Bangjie He
Bo Chen
Fangting Liu
Ziyan Chen
Jiuyi Zheng
Zhehao Shi
Tan Zhang
Liming Deng
Haitao Yu
Jinhuan Yang
Lijun Wu
Yunfeng Shan
Zhengping Yu
Xiaolei Chen
Yi Wang
Gang Chen
Publication date
01-02-2022
Publisher
Springer India
Published in
Hepatology International / Issue 1/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-021-10279-3

Other articles of this Issue 1/2022

Hepatology International 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.